Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial)

NCT03542461 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

125

Enrollment

OTHER

Sponsor class

Conditions

Squamous Non-small Cell Lung Cancer

Interventions

DRUG: Nivolumab 10 MG/ML Intravenous Solution
OTHER: Best Supportive Care

Sponsor

Gruppo Oncologico Italiano di Ricerca Clinica

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]